Integrated transcriptional profiling and genomic analyses reveal RPN2 and HMGB1 as promising biomarkers in colorectal cancer

Cell and Bioscience

Volumn 5, Issue 1, 2015, Pages

  Zhang, Jialing ^a,b,c   Yan, Bin ^d   Späth, Stephan Stanislaw ^e   Qun, Hu ^b   Cornelius, Shaleeka ^c   Guan, Daogang ^f   Shao, Jiaofang ^g   Hagiwara, Koichi ^h   Van Waes, Carter ^c   Chen, Zhong ^c   Su, Xiulan ^b   Bi, Yongyi ^a  

^a WUHAN UNIVERSITY   (China)

^b INNER MONGOLIA MEDICAL UNIVERSITY   (China)

^c NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS   (United States)

^d SHENZHEN INSTITUTES OF ADVANCED TECHNOLOGY   (China)

^e KAROLINSKA INSTITUTE   (Sweden)

^f HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

^g NANJING MEDICAL UNIVERSITY   (China)

^h JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Colorectal cancer; Gene regulation; Gene signature; Genomic alterations; Transcription factor

Indexed keywords

EID: 84941774003     PISSN: None     EISSN: 20453701     Source Type: Journal    
DOI: 10.1186/s13578-015-0043-9     Document Type: Article

References (58)

1. Kuipers EJ, Rosch T, Bretthauer M. Colorectal cancer screening-optimizing current strategies and new directions. Nature review. Clin Oncol. 2013;10(3):130-42.
2. Kuntz KM, Lansdorp-Vogelaar I, Rutter CM, Knudsen AB, van Ballegooijen M, Savarino JE, et al. A systematic comparison of microsimulation models of colorectal cancer: the role of assumptions about adenoma progression. Med Decis Mak Int J Soc Med Decis Mak. 2011;31(4):530-9.
3. Labianca R, Merelli B. Screening and diagnosis for colorectal cancer: present and future. Tumori. 2010;96(6):889-901.
4. Akiyoshi T, Kobunai T, Watanabe T. Recent approaches to identifying biomarkers for high-risk stage II colon cancer. Surg Today. 2012;42(11):1037-45.
5. Koelzer VH, Lugli A. The tumor border configuration of colorectal cancer as a histomorphological prognostic indicator. Front Oncol. 2014;18(4):29.
6. Lavery IC, De Campos-Lobato LF. How to evaluate risk and identify stage II patients requiring referral to a medical oncologist: a surgeon's perspective. Oncol N Y. 2010;24(1):14-6.
7. Fleming M, Ravula S, Tatishchev SF, Wang HL. Colorectal carcinoma: pathologic aspects. J Gastrointest Oncol. 2012;3(3):153-73.
8. Furlan D, Carnevali IW, Bernasconi B, Sahnane N, Milani K, Cerutti R, et al. Hierarchical clustering analysis of pathologic and molecular data identifies prognostically and biologically distinct groups of colorectal carcinomas. Mod Pathol. 2011;24(1):126-37.
9. Madhavan S, Gusev Y, Natarajan TG. Genome-wide multi-omics profiling of colorectal cancer identifies immune determinants strongly associated with relapse. Front Genet. 2013;20(4):236.
10. Sharif S, O'Connell MJ. Gene signatures in stage II colon cancer: a clinical review. Curr Colorectal Cancer Rep. 2012;8(3):225-31.
11. Chu D, Zhang Z, Li Y, Wu L, Zhang J, Wang W, Zhang J, et al. Prediction of colorectal cancer relapse and prognosis by tissue mRNA levels of NDRG2. Mol Cancer Ther Jan. 2011;10:47.
12. Vicuna B, Benson AB 3rd. Adjuvant therapy for stage II colon cancer: prognostic and predictive markers. J Nat Compr Cancer Net JNCCN. 2007;5(9):927-36.
13. Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I, Kerr D. Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer. 2009;9(7):489-99.
14. Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(3):466-74.
15. Ogino S, Nosho K, Irahara N, Shima K, Baba Y, Kirkner GJ, et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut. 2009;58(1):90-6.
16. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26(10):1626-34.
17. Razis E, Pentheroudakis G, Rigakos G, Bobos M, Kouvatseas G, Tzaida O, et al. EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab. J Cancer Res Clin Oncol. 2014;140(5):737-48.
18. Smith FM, Stephens RB, Kennedy MJ, Reynolds JV. P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer. 2005;92(9):1813.
19. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349(3):247-57.
20. Network Cancer Genome Atlas. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487(7407):330-7.
21. Shibayama M, Maak M, Nitsche U, Gotoh K, Rosenberg R, Janssen KP. Prediction of metastasis and recurrence in colorectal cancer based on gene expression analysis: ready for the clinic? Cancers. 2011;3:2858-69.
22. Watanabe T. Biomarker for high-risk patients with stage II colon cancer. Lancet Oncol. 2013;14(13):1247-8.
23. Sobin LH, Fleming ID. TNM classification of malignant tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer. 1997;80(9):1803-4.
24. Yan B, Li H, Yang X, Shao J, Jang M, Guan D, et al. Unraveling regulatory programs for NF-kappaB, p53 and microRNAs in head and neck squamous cell carcinoma. PLoS One. 2013;8(9):e73656.
25. Ethayathulla AS, Nguyen HT, Viadiu H. Crystal structures of the DNA-binding domain tetramer of the p53 tumor suppressor family member p73 bound to different full-site response elements. J Biol Chem. 2013;288(7):4744-54.
26. Martynova E, Pozzi S, Basile V, Dolfini D, Zambelli F, Imbriano C, et al. Gain-of-function p53 mutants have widespread genomic locations partially overlapping with p63. Oncotarget. 2012;3(2):132-43.
27. Kim J, Lee JH, Iyer VR. Global identification of Myc target genes reveals its direct role in mitochondrial biogenesis and its E-box usage in vivo. PLoS One. 2008;3(3):e1798.
28. Zeller KI, Jegga AG, Aronow BJ, O'Donnell KA, Dang CV. An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets. Genome Biol. 2003;4(10):R69.
29. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401-4.
30. Huqun, Ishikawa R, Zhang J, Miyazawa H, Goto Y, Shimizu Y, et al. Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer. Cancer. 2012;118(6):1599-606.
31. Sanz-Pamplona R, Berenguer A, Cordero D, Riccadonna S, Solé X, et al. Clinical value of prognosis gene expression signatures in colorectal cancer: a systematic review. PLoS One. 2012;7(11):e48877.
32. Oikawa T. ETS transcription factors: possible targets for cancer therapy. Cancer Sci. 2004;95(8):626-33.
33. Gronemeyer HJA. Gustafsson, and V. Laudet. Principles for modulation of the nuclear receptor superfamily. Nat Rev Drug Disc. 2004;3(11):950-64.
34. Sharma HW, Perez JR, Higgins-Sochaski K, Hsiao R, Narayanan R, et al. Transcription factor decoy approach to decipher the role of NF-kappa B in oncogenesis. Anticancer Res. 1996;16(1):61-9.
35. Hasselblatt P, Gresh L, Kudo H, Guinea-Viniegra J, Wagner EF. The role of the transcription factor AP-1 in colitis-associated and beta-catenin-dependent intestinal tumorigenesis in mice. Oncogene. 2008;27(47):6102-9.
36. Nakao K, Mehta KR, Fridlyand J, Moore DH, Jain AN, Lafuente A, et al. High-resolution analysis of DNA copy number alterations in colorectal cancer by array-based comparative genomic hybridization. Carcinogenesis. 2004;25(8):1345-57.
37. Gordziel C, Bratsch J, Moriggl R, Knösel T, Friedrich K. Both STAT1 and STAT3 are favourable prognostic determinants in colorectal carcinoma. Br J Cancer. 2013;109(1):138-46.
38. Camps J, Nguyen QT, Padilla-Nash HM, Knutsen T, McNeil NE, Wangsa D, et al. Integrative genomics reveals mechanisms of copy number alterations responsible for transcriptional deregulation in colorectal cancer. Genes Chromosom Cancer. 2009;48(11):1002-17.
39. Henrichsen CN, Chaignat E, Reymond A. Copy number variants, diseases and gene expression. Hum Mol Genet. 2009;18(R1):R1-8.
40. Yi JM, Dhir M, Van Neste L, Downing SR, Jeschke J, Glöckner SC, et al. Genomic and epigenomic integration identifies a prognostic signature in colon cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2011;17(6):1535-45.
41. Yao X, Zhao G, Yang H, Hong X, Bie L, Liu G. Overexpression of high-mobility group box 1 correlates with tumor progression and poor prognosis in human colorectal carcinoma. J Cancer Res Clin Oncol. 2010;136(5):677-84.
42. Slaby O, Sobkova K, Svoboda M, Garajova I, Fabian P, Hrstka R. Significant overexpression of Hsp110 gene during colorectal cancer progression. Oncol Rep. 2009;21(5):1235-41.
43. Southern SL, Collard TJ, Urban BC, Skeen VR, Smartt HJ, Hague A, et al. BAG-1 interacts with the p50-p50 homodimeric NF-kappaB complex: implications for colorectal carcinogenesis. Oncogene. 2012;31(22):2761-72.
44. Kang R, Zhang Q, Zeh HJ 3rd, Lotze MT, Tang D. HMGB1 in cancer: good, bad, or both? Clin Cancer Res Off J Am Assoc Cancer Res. 2013;19(15):4046-57.
45. Süren D, Yildirim M, Demirpençe O, Kaya V, Alikanoğlu AS, Bülbüller N, et al. The role of high mobility group box 1 (HMGB1) in colorectal cancer. Med Sci Monit. 2014;31(20):530-7.
46. Ueda M, Takahashi Y, Shinden Y, Sakimura S, Hirata H, Uchi R, et al. Prognostic significance of high mobility group box 1 (HMGB1) expression in patients with colorectal cancer. Anticancer Res. 2014;34(10):5357-62.
47. Zhang CC, Gdynia G, Ehemann V, Roth W. The HMGB1 protein sensitizes colon carcinoma cells to cell death triggered by pro-apoptotic agents. nt. J Oncol. 2015;46(2):667-76.
48. Zhu L, Li X, Chen Y, Fang J, Ge Z. High-mobility group box 1: a novel inducer of the epithelial-mesenchymal transition in colorectal carcinoma. Cancer Lett. 2015;357(2):527-34.
49. Honma K, Iwao-Koizumi K, Takeshita F, Yamamoto Y, Yoshida T, Nishio K, et al. RPN2 gene confers docetaxel resistance in breast cancer. Nat Med. 2008;14(9):939-48.
50. Takahashi RU, Takeshita F, Honma K, Ono M, Kato K, Ochiya T. Ribophorin II regulates breast tumor initiation and metastasis through the functional suppression of GSK3 beta. Sci Rep. 2013;3:2474.
51. Vilar E, Gruber SB. Microsatellite instability in colorectal cancer-the stable evidence. Nature reviews. Clin Oncol. 2010;7(3):153-62.
52. Nanashima A, Yamaguchi H, Yasutake T, Sawai T, Kusano H, Tagawa Y, et al. Gain of chromosome 20 is a frequent aberration in liver metastasis of colorectal cancers. Dig Dis Sci. 1997;42:1388-93.
53. Loo LW, Tiirikainen M, Cheng I, Lum-Jones A, Seifried A, Church JM, et al. Integrated analysis of genome-wide copy number alterations and gene expression in microsatellite stable, CpG island methylator phenotype-negative colon cancer. Genes Chromosomes Cancer. 2013;52(5):450-66.
54. Kurashige J, Watanabe M, Iwatsuki M, Kinoshita K, Saito S, Nagai Y, et al. RPN2 expression predicts response to docetaxel in oesophageal squamous cell carcinoma. Br J Cancer. 2012;107(8):1233-8.
55. Lian M, Fang J, Han D, Ma H, Feng L, Wang R, et al. Microarray gene expression analysis of tumorigenesis and regional lymph node metastasis in laryngeal squamous cell carcinoma. PLoS One. 2013;8(12):e84854.
56. Fujiwara T, Takahashi RU, Kosaka N, Nezu Y, Kawai A, et al. RPN2 gene confers osteosarcoma cell malignant phenotypes and determines clinical prognosis. Molecular therapy. Nucleic Acids. 2014;3:e189.
57. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20(3):776-90.
58. Fujita Y, Takeshita F, Mizutani T, Ohgi T, Kuwano K, Ochiya T. A novel platform to enable inhaled naked RNAi medicine for lung cancer. Scientific Rep. 2013;3:3325.